Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes-Reference-Cited by-同舟云学术

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes

Published:2011-01-11 Issue:3 Volume:2 Page:224-229
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Romine Jeffrey L.¹,St. Laurent Denis R.¹,Leet John E.²,Martin Scott W.¹,Serrano-Wu Michael H.¹,Yang Fukang¹,Gao Min³,O’Boyle Donald R³,Lemm Julie A.³,Sun Jin-Hua³,Nower Peter T.³,Huang Xiaohua (Stella)⁴,Deshpande Milind S.¹,Meanwell Nicholas A.¹,Snyder Lawrence B.¹

Affiliation:

1. Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

2. Synthesis & Analysis Technology Team, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

3. Department of Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

4. Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml1002647

Reference25 articles.

1. Global epidemiology and burden of hepatitis C

2. Peginterferon and Ribavirin for Chronic Hepatitis C

3. Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it